Please login to the form below

Not currently logged in
Email:
Password:

multiple melanoma

This page shows the latest multiple melanoma news and features for those working in and with pharma, biotech and healthcare.

Sanofi/Regeneron’s IO latecomer Libtayo approved in Europe

Sanofi/Regeneron’s IO latecomer Libtayo approved in Europe

Sanofi and Regeneron aren’t holding back on the scale of their research programme, and these include trials in squamous cell carcinoma of the head and neck, melanoma, colorectal cancer, prostate ... cancer, multiple myeloma, Hodgkin’s lymphoma and non

Latest news

  • BMS wins first US immuno-oncology paediatric licence BMS wins first US immuno-oncology paediatric licence

    FDA gives the green light to expanded use of its melanoma treatment Yervoy. ... led analysts at EvaluatePharma to predict that Merck &Co’s melanoma drug Keytruda (pembrolizumab) will topple Opdivo as the top-selling PD-1/PD-L1 inhibitor by 2022.

  • BMS' Empliciti approved by FDA for multiple myeloma BMS' Empliciti approved by FDA for multiple myeloma

    Clearedfor use in with Celgene's Revlimid and corticosteroid dexamethasone.  . Bristol-Myers Squibb's Empliciti has become the third new treatment approved for multiple myeloma in the US in a fortnight. ... The new therapies provide new options for

  • Pfizer and Merck flesh out Xalkori alliance details Pfizer and Merck flesh out Xalkori alliance details

    BMS' Opdivo is used to treat melanoma and non-small cell lung cancer (NSCLC), with Merck's Keytruda (pembrolizumab) currently approved for melanoma only. ... Both drugs have multiple new indications coming through the pipeline, while additional

  • AB Science on track for phase III data in Alzheimer's this year AB Science on track for phase III data in Alzheimer's this year

    The drug is in trials for a host of cancer indications, including phase III studies in gastrointestinal stromal tumours (GIST), colorectal cancer, multiple myeloma and melanoma, as well as phase II ... Outside the cancer area it is being trialled in

  • GSK and Bayer strike new biotech cancer deals GSK and Bayer strike new biotech cancer deals

    It seems GSK still has interests in cancer, however, and will be looking to make the most of Adaptimmune's technology in cancer immunotherapies, which has shown promise in treating multiple ... myeloma, melanoma, sarcoma and ovarian cancer.

More from news
Approximately 2 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Virgo Health

Virgo Health is an award-winning global healthcare communications and medical education agency. We dispense pioneering and creative campaigns, driven by...

Latest intelligence

Theodora Harold
A snapshot of Crescendo Biologics
PME talks to CEO Theodora Harold...
eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...

Infographics